Sector consensus Gilead Sciences, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2025-12-16 EST			After hours 16:15:58
118.78 ^USD	-0.83%		118.00	-0.66%

12-15	RedHill Biopharma Ltd.'s Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells	CI
12-15	Gilead HIV combo of bictegravir & lenacapavir hits phase 3 goal	RE

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Average Target P.	Objective/dr gap	Nbr of analysts
GILEAD SCIENCES, INC.	US$132.38	+10.52%	26
ELI LILLY AND COMPANY	US$1,075.07	+1.21%	27
JOHNSON & JOHNSON	US$207.75	-3%	24
ABBVIE INC.	US$244.29	+7.4%	28
ROCHE HOLDING AG	CHF 323.28	+0.43%	18
ASTRAZENECA PLC	GBX 201.39	+10.56%	19
NOVARTIS AG	CHF 135.31	+0.39%	19
MERCK & CO., INC.	US$108.04	+7.76%	26
NOVO NORDISK A/S	DKK 393.29	+24.3%	20
AMGEN INC.	US$325.88	+0.18%	27
PFIZER INC.	US$28.87	+9.24%	24
SANOFI	€105.1	+30.4%	21
VERTEX PHARMACEUTICALS INCORPORATED	US$489.48	+7.41%	25
BRISTOL-MYERS SQUIBB COMPANY	US$53.82	-0.87%	22
GSK PLC	GBX 18.64	+1.64%	18
CHUGAI PHARMACEUTICAL CO., LTD.	JP¥8,571.43	+0.67%	14
JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD	CN¥81.04	+32.02%	18
ALNYLAM PHARMACEUTICALS, INC.	US$491.92	+25.65%	24
TAKEDA PHARMACEUTICAL COMPANY LIMITED	JP¥4,946.14	+10.38%	14
Average	943.85	+9.28%	22
Weighted average by Cap.	622.98	+5.53%	23